ClinicalTrials.gg
CompletedNCT00319111BENEFIT OLUpdated Feb 4, 2025Results posted

Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

A Phase 3 interventional study of bosentan in Pulmonary Hypertension, sponsored by Actelion. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
151
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing bosentan in Hypertension, Pulmonary — none open to participants now, none under way, none of them phase 3. Bosentan · Hypertension, Pulmonary.

Enrollment
5th of 19
151 · median 22
Started
2006
with 6 others
Phase 3
8 of 19
none open now
Registered
7th of 19
by date
Lead sponsor
9 of 19
Actelion

Among the 19 studies testing bosentan in Hypertension, Pulmonary, this one is the 5th largest by enrollment, is one of 7 that started in 2006, is one of 8 in phase 3, and was the 7th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

None of the 19 studies testing bosentan in Hypertension, Pulmonary is open now. The open studies under Hypertension, Pulmonary, anywhere →

About bosentan

Bosentan: first FDA approval 2001 (TRACLEER), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing bosentan in Hypertension, Pulmonary as a file.
02

Study summary

The present trial investigates the long-term safety, tolerability and efficacy of bosentan in patients with inoperable CTEPH.

03

Conditions studied

  • Pulmonary Hypertension

Keywords

  • pulmonary hypertension
  • bosentan
  • BENEFIT
  • CTEPH
  • inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients having completed the 16-week treatment period of protocol AC-052-366 (NCT00313222)
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Any major violation of protocol AC-052-366 (NCT00313222)
  • Pregnancy or breast-feeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Bosentan

    Open label bosentan treatment

    Drug: bosentan

Interventions

  • Oral bosentan * Initial dose: 62.5 mg twice a day (b.i.d.) for 4 weeks for all patients * Maintenance dose: 125 mg b.i.d. (62.5 mg b.i.d. if weight \< 40 kg)

06

What researchers measure

Primary outcomes

  1. Change From Baseline to All Assessed Time Points in 6-minute Walk Test (6MWT) Distance

    Exercise capacity was assessed using the 6MWT. Area used for testing had to be a minimum of 30m in length and 2-3m in width, with 3m gradations. Areas were well ventilated with air temperature controlled. The test was administered at the same time of day and by the same tester throughout the study. The tester measured the distance walked by non-encouraged patients during the timed 6min period. If the test was stopped before 6 minutes, the main reason for stopping the test was recorded. The tester measured the distance walked by patients during the timed 6min period.

    Time frame: Until discontinuation of study drug, up to 3.3 years

  2. Change From Baseline to All Assessed Time Points in Borg Dyspnea Index

    Maximal dyspnea during the walk test was assessed by the patient using the Borg dyspnea index. Immediately following each walk test, patients rated perceived maximal breathlessness during the walk test on a 12-point scale (0 \[nothing at all\], 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 \[maximum ever experienced\]).

    Time frame: Until discontinuation of study drug, up to 3.3 years

  3. Disease Severity - Number of Patients Showing Improvement by One Class or More in World Health Organisation (WHO) Functional Classification of Pulmonary Hypertension (PH)

    Disease severity was assessed by WHO classification of PH criteria: Class I: no limitation of physical activity (PA). Ordinary PA: no undue dyspnea/fatigue, chest pain, near syncope. Class II: slight limitation of PA. Comfortable at rest. Ordinary PA: undue dyspnea/fatigue, chest pain, near syncope. Class III: marked limitation of PA. Comfortable at rest. Less than ordinary PA: undue dyspnea/fatigue, chest pain, near syncope. Class IV: inability to carry out PA without symptoms. Right heart failure. Dyspnea/fatigue may even have been present at rest. Discomfort increased by any PA.

    Time frame: Until discontinuation of study drug, up to 3.3 years

  4. Time to Clinical Worsening up to End-of-study

    An event of clinical worsening was defined as death during the treatment period, a treatment-emergent adverse event that led to permanent discontinuation of study treatment and with outcome death, hospitalization due to worsening pulmonary hypertension, or lung transplantation. Patients are censored at 1 day after the end of treatment or at day of pulmonary endarterectomy if earlier.

    Time frame: Until discontinuation of study drug, up to 3.3 years

Secondary outcomes

  1. Number of Patients With an Adverse Event(s) Leading to Premature Discontinuation of Study Medication

    Time frame: Until discontinuation of study drug, up to 3.3 years

  2. Number of Patients Experiencing a Serious Adverse Event(s) up to 28 Days After Study Medication Discontinuation

    Time frame: 28 days after discontinuation of study drug, up to 3.3 years

  3. Occurrence of Liver Function Test and Hemoglobin Abnormality

    Number of patients with an increase in liver aminotransferases to \>3 times upper limit of normal (ULN) or a decrease in hemoglobin concentration to ≤10 g/dL

    Time frame: Until discontinuation of study drug, up to 3.3 years

07

Results

Posted Dec 31, 2012

Participant flow

Patients were enrolled at 26 centers in 13 countries (Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Italy, The Netherlands, Poland, Spain, UK, and USA. The first patient started treatment on 26 January 2006 and the last patient received their last dose of study treatment on 23 February 2009.

Participant flow — Overall Study
MilestoneBosentan
Started151
Completed104
Not completed47
Withdrew: Adverse event20
Withdrew: Withdrawal of consent11
Withdrew: Death9
Withdrew: Lack of clinical improvement4
Withdrew: Administrative2
Withdrew: Treatment failure1

Outcome measures

PrimaryChange From Baseline to All Assessed Time Points in 6-minute Walk Test (6MWT) Distance

Exercise capacity was assessed using the 6MWT. Area used for testing had to be a minimum of 30m in length and 2-3m in width, with 3m gradations. Areas were well ventilated with air temperature controlled. The test was administered at the same time of day and by the same tester throughout the study. The tester measured the distance walked by non-encouraged patients during the timed 6min period. If the test was stopped before 6 minutes, the main reason for stopping the test was recorded. The tester measured the distance walked by patients during the timed 6min period.

Time frame:
Until discontinuation of study drug, up to 3.3 years
Reported as:
Mean · walk distance change from baseline (m)
Change From Baseline to All Assessed Time Points in 6-minute Walk Test (6MWT) Distance
walk distance change from baseline (m)Bosentan
month 68.4 ± 66.4
month 1218.2 ± 64.0
month 1817.7 ± 63.1
month 2420.2 ± 64.8
end of the treatment period16.9 ± 69.4
PrimaryChange From Baseline to All Assessed Time Points in Borg Dyspnea Index

Maximal dyspnea during the walk test was assessed by the patient using the Borg dyspnea index. Immediately following each walk test, patients rated perceived maximal breathlessness during the walk test on a 12-point scale (0 \[nothing at all\], 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 \[maximum ever experienced\]).

Time frame:
Until discontinuation of study drug, up to 3.3 years
Reported as:
Mean · Scores on a scale
Change From Baseline to All Assessed Time Points in Borg Dyspnea Index
Scores on a scaleBosentan
month 6-0.5 ± 1.7
month 12-0.4 ± 1.8
month 18-0.1 ± 1.9
month 24-0.1 ± 1.9
end of the treatment period-0.2 ± 2.1
PrimaryDisease Severity - Number of Patients Showing Improvement by One Class or More in World Health Organisation (WHO) Functional Classification of Pulmonary Hypertension (PH)

Disease severity was assessed by WHO classification of PH criteria: Class I: no limitation of physical activity (PA). Ordinary PA: no undue dyspnea/fatigue, chest pain, near syncope. Class II: slight limitation of PA. Comfortable at rest. Ordinary PA: undue dyspnea/fatigue, chest pain, near syncope. Class III: marked limitation of PA. Comfortable at rest. Less than ordinary PA: undue dyspnea/fatigue, chest pain, near syncope. Class IV: inability to carry out PA without symptoms. Right heart failure. Dyspnea/fatigue may even have been present at rest. Discomfort increased by any PA.

Time frame:
Until discontinuation of study drug, up to 3.3 years
Reported as:
Number · participants with improved WHO class
Disease Severity - Number of Patients Showing Improvement by One Class or More in World Health Organisation (WHO) Functional Classification of Pulmonary Hypertension (PH)
participants with improved WHO classBosentan
month 626
month 1230
month 1833
month 2433
end of treatment period30
PrimaryTime to Clinical Worsening up to End-of-study

An event of clinical worsening was defined as death during the treatment period, a treatment-emergent adverse event that led to permanent discontinuation of study treatment and with outcome death, hospitalization due to worsening pulmonary hypertension, or lung transplantation. Patients are censored at 1 day after the end of treatment or at day of pulmonary endarterectomy if earlier.

Time frame:
Until discontinuation of study drug, up to 3.3 years
Reported as:
Number · participants
Time to Clinical Worsening up to End-of-study
participantsBosentan
month 6 (censored)11
month 6 (events)8
month 12 (censored)18
month 12 (events)11
month 18 (censored)25
month 18 (events)15
month 24 (censored)34
month 24 (events))19
month 30 (censored)78
month 30 (events)20
month 36 (censored)122
month 36 (events)21
end of study (censored)130
end of study (events)21
SecondaryNumber of Patients With an Adverse Event(s) Leading to Premature Discontinuation of Study Medication
Time frame:
Until discontinuation of study drug, up to 3.3 years
Reported as:
Number · participants
Number of Patients With an Adverse Event(s) Leading to Premature Discontinuation of Study Medication
participantsBosentan
Number of Patients With an Adverse Event(s) Leading to Premature Discontinuation of Study Medication28
SecondaryNumber of Patients Experiencing a Serious Adverse Event(s) up to 28 Days After Study Medication Discontinuation
Time frame:
28 days after discontinuation of study drug, up to 3.3 years
Reported as:
Number · participants
Number of Patients Experiencing a Serious Adverse Event(s) up to 28 Days After Study Medication Discontinuation
participantsBosentan
Number of Patients Experiencing a Serious Adverse Event(s) up to 28 Days After Study Medication Discontinuation51
SecondaryOccurrence of Liver Function Test and Hemoglobin Abnormality

Number of patients with an increase in liver aminotransferases to \>3 times upper limit of normal (ULN) or a decrease in hemoglobin concentration to ≤10 g/dL

Time frame:
Until discontinuation of study drug, up to 3.3 years
Reported as:
Number · participants
Occurrence of Liver Function Test and Hemoglobin Abnormality
participantsBosentan
Increase in liver function test27
Decrease in hemoglobin9

Adverse events

Collected over Up to 28 days after the end of study drug. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bosentan—51/151 (33.8%)11/151 (7.3%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventBosentan
Right ventricular failureCardiac disorders11/151
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders5/151
Liver function test abnormalInvestigations5/151
Cardiac failureCardiac disorders4/151
Atrial fibrillationCardiac disorders3/151
Atrial flutterCardiac disorders3/151
DyspnoeaRespiratory, thoracic and mediastinal disorders3/151
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders3/151
AnaemiaBlood and lymphatic system disorders3/151
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/151
Most frequent other events
Most frequent other events
EventBosentan
HEPATIC ENZYME INCREASEDInvestigations3/151
LIVER FUNCTION TEST ABNORMALInvestigations3/151
ANOREXIAMetabolism and nutrition disorders1/151
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations1/151
DYSPEPSIAGastrointestinal disorders1/151
NASAL MUCOSAL DISORDERRespiratory, thoracic and mediastinal disorders1/151
NAUSEAGastrointestinal disorders1/151
PULMONARY HYPERTENSIONRespiratory, thoracic and mediastinal disorders1/151
VOMITINGGastrointestinal disorders1/151

Baseline characteristics

Age, Continuous
Age, Continuous(years)Bosentan
Mean63.1 ± 11.7
Age, Customized
Age, Customized(participants)Bosentan
25-81 years151
Sex: Female, Male
Sex: Female, Male(Participants)Bosentan
Female100
Male51
Region of Enrollment
Region of Enrollment(participants)Bosentan
Australia17
Austria10
Belgium8
Canada6
Czech Republic20
France18
Germany14
Italy28
Netherlands11
Poland9
Spain3
United Kingdom2
United States5
Six-minute walk test (6MWT)
Six-minute walk test (6MWT)(walk distance (m))Bosentan
Mean345.2 ± 93.4
Borg dyspnea index
Borg dyspnea index(points on a scale)Bosentan
Mean4.2 ± 2.2
World Health Organisation (WHO) functional class
World Health Organisation (WHO) functional class(participants)Bosentan
Class I3
Class II41
Class III91
Class IV4
Unassessed12
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Feb 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2012, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2006
First posted
Apr 27, 2006
Start
Jan 2006
Primary completionActual
Feb 2009
CompletionActual
Apr 2009
Results first posted
Dec 31, 2012
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00319111
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Apr 27, 2006
Start date
Jan 2006
Primary completion
Feb 2009
Completion
Apr 2009
Results posted
Dec 31, 2012
Last update
Feb 4, 2025
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bosentan

Start the discussion